COIN, NBIX and UPST have been added to the Zacks Rank #5 (Strong Sell) List on February 18th, 2026.

JPMorgan Chase and Co. increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 11.0% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,730,152 shares of the company's stock after purchasing an additional 468,405 shares during the period. JPMorgan

Neurocrine Biosciences has successfully diversified beyond Ingrezza, with Crenessity's rapid adoption validating its multi-franchise commercial strategy. NBIX's late-stage neuropsychiatry pipeline, including muscarinic agonist and glutamate modulator programs, appears significantly underappreciated by the market. Ingrezza's revenue growth is slowing due to pricing pressures, but NBIX's robust cash position and pipeline investments support long-term growth into the 2030s.

Neurocrine Biosciences Inc (NASDAQ: NBIX) on Wednesday reported fourth-quarter adjusted earnings of $1.88 per share, missing the consensus of $1.89.

Neurocrine Biosciences reported largely in-line Q4 results, with better-than-expected Crenessity sales; guidance for 2026 was in-line with published expectations but arguably a bit lackluster. NBIX's pipeline is deepening, but meaningful clinical catalysts are unlikely before 2027, when Phase III readouts in MDD and schizophrenia are expected. Absent clinical updates, Street concerns over future pricing pressure on Ingrezza could drive muted market performance, but a recent head-to-head study versus Austedo could drive some upside.

Neurocrine Biosciences, Inc. (NBIX) Q4 2025 Earnings Call Transcript

While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.88 per share, missing the Zacks Consensus Estimate of $2.25 per share. This compares to earnings of $1 per share a year ago.

Total Fourth-Quarter and Full-Year 2025 Net Product Sales of $798.3 Million and $2.83 Billion, Representing Year-Over-Year Growth of 29% and 22%, Respectively INGREZZA® (valbenazine) Full Year 2026 Net Product Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter ended December 31, 2025. "Our 2025 performance reflects the strength and durability of our commercial business and meaningful progress we are making transforming Neurocrine into a broader, more diversified biopharmaceutical company," said Kyle W.

Get a deeper insight into the potential performance of Neurocrine (NBIX) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.